Evidence map›Paper›PMID 42304720›Full record

ArticlePigment cell & melanoma research2026

MelOD: The Melanoma Omics Dashboard for Multimodal Data Exploration.

Paul Sastourne-Haletou, Adam Walker, Dania Annuar, Ipsita Subudhi, Alcida Karz, Pietro Berico, Paola Angulo Salgado, Milad Ibrahim, Iman Osman, Markus Schober and 2 more

Abstract read
In one paragraph

Article in Pigment cell & melanoma research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Paul Sastourne-HaletouDivision of Precision Medicine, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.ORCID https://orcid.org/0009-0006-4022-545X
Adam WalkerDivision of Precision Medicine, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.
Dania AnnuarDivision of Precision Medicine, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.
Ipsita SubudhiDivision of Precision Medicine, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.
Alcida KarzDivision of Precision Medicine, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.
Pietro BericoDepartment of Pathology, NYU Grossman School of Medicine, New York, New York, USA.
Paola Angulo SalgadoDepartment of Pathology, NYU Grossman School of Medicine, New York, New York, USA.
Milad IbrahimRonald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York, USA.
Iman OsmanRonald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York, USA.
Markus SchoberRonald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York, USA.
Eva HernandoDepartment of Pathology, NYU Grossman School of Medicine, New York, New York, USA.
Kelly V RugglesDivision of Precision Medicine, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.

Funding

Project 4P50CA225450 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI OSMAN, IMAN, WEBER, JEFFREY S · 2019 to 2025
$12.5M
Project 3: The Evolving Role of Regional Lymph Nodes in Melanoma ProgressionU54CA263001 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Kelly Valentine Ruggles · 2022 to 2026
$11.6M
NCI NIH HHS P50 CA225450NCI NIH HHS U54 CA263001NYULH Metastasis Research Network Center NIH/NCI 1U54CA263001NYU Melanoma SPORE NCI P50 CA225450
6 · The paper itself

Abstract

We present MelOD (Melanoma Omics Dashboard), a free, web-based interactive platform integrating preprocessed data from 16 melanoma studies, including eight bulk transcriptomics, six single-cell RNA-seq, and two proteomics datasets. MelOD provides user-friendly visualization and analysis tools, differential expression, dimensionality reduction, clustering, correlation, and survival analysis without requiring local computational resources. Several datasets include annotations for immunotherapy response, facilitating exploration of resistance and response signatures. Built on RShiny with optimized handling of large datasets, MelOD supports real-time hypothesis generation, cross-study validation, and community dataset contributions. Freely accessible online, MelOD lowers barriers to multi-omics research in melanoma and related fields.

Indexed as

MelanomaSoftwareDashboard SystemsHumansMultiomicsProteomicsdata visualizationinteractive dashboardmelanomaproteomicssingle‐cell RNA‐seqtranscriptomics

Identifiers

PMID42304720
PMCPMC13599787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.